Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review

Cachexia has significant impact on the patients' quality of life and prognosis. It is frequently observed in patients with cancer, especially in advanced stages, but prevalence data for the overall population are lacking. Good quality estimates of cancer cachexia in general and for each of the major cancer types would be highly relevant for potential treatment development efforts in this field. Both the USA and European Union (EU) have implemented special clinical development rules for such rare disorders what are called ‘orphan diseases’. The cut‐off level for a disease to be considered an orphan disease in the USA is 200 000 people (0.06% of the population) and EU is 5 per 10 000 people (0.05% of the population).

[1]  M. Korc,et al.  Cancer-associated cachexia , 2018, Nature Reviews Disease Primers.

[2]  S. Anker,et al.  Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017 , 2017, Journal of cachexia, sarcopenia and muscle.

[3]  J. Wright,et al.  Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Farcomeni,et al.  Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study , 2017, Oncotarget.

[5]  W. Doehner,et al.  Cardiac muscle wasting in individuals with cancer cachexia , 2017, ESC heart failure.

[6]  P. Fayers,et al.  The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis , 2017, Journal of cachexia, sarcopenia and muscle.

[7]  L. Gordon,et al.  Impact of cachexia on outcomes in aggressive lymphomas , 2017, Annals of Hematology.

[8]  S. Anker,et al.  Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016 , 2016, Journal of cachexia, sarcopenia and muscle.

[9]  S. von Haehling,et al.  Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference , 2016, Journal of cachexia, sarcopenia and muscle.

[10]  M. Schlumberger,et al.  A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer , 2015, Clinical Cancer Research.

[11]  M. Muscaritoli,et al.  Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach. , 2015, Critical reviews in oncology/hematology.

[12]  C. Andresen,et al.  A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment , 2015, Cancer.

[13]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[14]  C. Blanchette,et al.  One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA , 2014, Drugs in context.

[15]  J. Nho,et al.  Depression and appetite: predictors of malnutrition in gynecologic cancer , 2014, Supportive Care in Cancer.

[16]  E. Lemarié,et al.  Prevalence of malnutrition and current use of nutrition support in patients with cancer. , 2014, JPEN. Journal of parenteral and enteral nutrition.

[17]  Connie M. Rhee,et al.  Why cachexia kills: examining the causality of poor outcomes in wasting conditions , 2013, Journal of cachexia, sarcopenia and muscle.

[18]  J. Ferlay,et al.  Global estimates of cancer prevalence for 27 sites in the adult population in 2008 , 2013, International journal of cancer.

[19]  M. Grant,et al.  Management of Anorexia-Cachexia in Late Stage Lung Cancer Patients. , 2012, Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association.

[20]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[21]  S. Phillips,et al.  Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. , 2011, The Journal of urology.

[22]  J. Bae,et al.  Prevalence and risk factors of malnutrition among cancer patients according to tumor location and stage in the National Cancer Center in Korea. , 2010, Nutrition.

[23]  P. Bachmann,et al.  Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres , 2010, British Journal of Cancer.

[24]  K. Fox,et al.  Estimation of Cachexia among Cancer Patients Based on Four Definitions , 2009, Journal of oncology.

[25]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[26]  H. Friess,et al.  Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.

[27]  John T. Wei,et al.  The effects of adjusting for case mix on mortality and length of stay following radical cystectomy. , 2006, The Journal of urology.

[28]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[29]  C. Jara,et al.  An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer. , 2005, Clinical nutrition.

[30]  R. Figlin,et al.  Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. , 2004, The Journal of urology.

[31]  H. Thaler,et al.  Symptom prevalence, characteristics and distress in a cancer population , 1994, Quality of Life Research.

[32]  R. Figlin,et al.  Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. , 2003, The Journal of urology.

[33]  A. Inui.  Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management , 2002, CA: a cancer journal for clinicians.

[34]  J. Lees.  Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. , 1999, European journal of cancer care.

[35]  A. Norman,et al.  Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? , 1998, European journal of cancer.

[36]  K. Forbes.  Palliative care in patients with cancer of the head and neck. , 1997, Clinical otolaryngology and allied sciences.

[37]  A. Auvinen,et al.  Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. , 1996, Journal of pain and symptom management.

[38]  M. Nair,et al.  Evaluation of symptomatology in planning palliative care.: 22 , 1994 .

[39]  R. Sankaranarayanan,et al.  Evaluation of symptomatology in planning palliative care , 1993, Palliative medicine.

[40]  D. Walsh,et al.  Symptoms of lung cancer , 1992 .

[41]  D. Walsh,et al.  Symptoms of pancreatic cancer. , 1991, Journal of pain and symptom management.

[42]  V. Mor,et al.  The end stage cancer patient: terminal common pathway. , 1988, The Hospice journal.

[43]  I. Hessov,et al.  Nutritional status of patients with cancer of the bladder before and during radiation therapy. Influence on survival? , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  D. Sleijfer,et al.  The effect of continuous enteral tube feeding on various nutritional parameters in patients with disseminated malignant melanoma during intensive chemotherapy. , 1983, Clinical nutrition.

[45]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[46]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[47]  S. Warren.  THE IMMEDIATE CAUSES OF DEATH IN CANCER , 1932 .